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Preterm birth (PTB) continues to be a global health challenge. An over-production of inflam-
matory cytokines and chemokines, as well as an altered maternal vaginal microbiome has
been implicated in the pathogenesis of inflammation/infection-associated PTB. Lactobacil-
lus represents the dominant species in the vagina of most healthy pregnant women. The
depletion of Lactobacillus in women with bacterial vaginosis (BV) has been associated with
an increased risk of PTB. It remains unknown at what point an aberrant vaginal microbiome
composition specifically induces the cascade leading to PTB. The ability of oral or vaginal
lactobacilli probiotics to reduce BV occurrence and/or dampen inflammation is being con-
sidered as a means to prevent PTB. Certain anti-inflammatory properties of lactobacilli
suggest potential mechanisms. To date, clinical studies have not been powered with suf-
ficiently high rates of PTB, but overall, there is merit in examining this promising area of
clinical science.
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INTRODUCTION
The etiology of preterm birth (PTB) is multifactorial: 50% of the
cases are idiopathic while 20–40% are disease specific or medically
indicated deliveries such as pre-eclampsia or fetal growth restric-
tion (FGR), which require delivery (1, 2). The remaining 25–30%
of PTB can be attributed to intrauterine infection and/or inflam-
mation (1, 2). Microorganisms can invade the uterus through the
fallopian tube in a retrograde fashion from the abdominal cavity,
hematogenously via the placenta or ascending through the cervix
and vagina (3).
MECHANISM OF INFLAMMATION AND
INFECTION-ASSOCIATED PRETERM LABOR
Microorganisms can reach the maternal intrauterine tissues
through any mucosal surface and secrete phospholipase A2 to act
on membrane phospholipids and form unesterified arachidonic
acid (AA). The AA is converted into endoperoxide products and
subsequently into primary prostaglandins (PGs; PGE2, PGF2a)
by PGH synthase-2 and isomerases, respectively. Alternatively,
some microbes secrete endotoxins, such as lipopolysaccharides
(LPS), which specifically bind toll-like receptor 4 (TLR4) and
activate the nuclear factor κ light-chain-enhancer of activated B
cells (NFkB) pathway to induce pro-inflammatory cytokine and
chemokine gene expression in the intrauterine tissues (amnion,
chorion, and decidua), macrophages, and endothelial cells (4,
5). Pro-inflammatory cytokines interact with each other as well
as with PGs in a feed-forward cascade, hence amplifying the
inflammatory response (6, 7). Furthermore, pro-inflammatory
cytokines enhance the expression of matrix metalloproteinase
(MMPs), which are zinc-dependent enzymes that catalyze the
degradation of collagen constituted-extracellular matrix of the
cervix, fetal membrane, placenta, and uterus (8–11). Elevated lev-
els of MMP-9 in the maternal plasma, and MMP-3 and MMP-8 in
the amniotic fluid are associated with preterm labor (PTL) and/or
microbial invasion of the amniotic cavity (11–13).
Bacteria and viruses can also cross an intact chorioamniotic
membrane and induce intra-amniotic inflammation, a condition
termed the fetal inflammatory response syndrome (FIRS). Ele-
vated interleukin (IL)-6 and LPS-binding proteins are observed in
the umbilical cord blood in FIRS-affected preterm neonates (14–
17). Pathogenic microorganisms such as Ureaplasma urealyticum
and Mycoplasma hominis have been isolated from the umbilical
cord blood of very preterm newborns (18). Intrauterine infection
can also lead to activation of the fetal hypothalamic–pituitary–
adrenal (HPA) axis giving rise to increased cortisol biosynthesis
and decreased metabolism of maternal cortisol to inactive corti-
sone by 11β-hydroxysteroid dehydrogenase-2 in the placenta (19).
Sustained stimulation of placental corticotropin releasing hor-
mone by fetal cortisol leads to an increase in PG production (20).
PG in turn promotes a positive feed-forward loop that comprise an
increase in the expression and production of gap junctions such as
connexin 43 and pro-inflammatory cytokines including IL-6 and
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tumor necrosis factor alpha (TNFα) (20). Together, they promote
synchronous and forceful myometrial contractions and PTL.
In short, microbes are well known for their involvement in
PTL. In order to understand the origins of these organisms, stud-
ies have been undertaken on many sites in the reproductive tract,
particularly the vagina.
ALTERED VAGINAL MICROBIOME AND PTB
The vaginal microbiota composition is dynamic throughout a
woman’s life. Before puberty, it is dominated by anaerobic bac-
teria (21). Rising estrogen levels at puberty lead to an increase in
mucosal glycogen production whose metabolized substrates sup-
port vaginal colonization with lactobacilli (21, 22). This is one
reason for the vagina to be highly colonized by lactobacilli during
reproductive years and pregnancy (23). At menopause, lactobacilli
abundance decreases coinciding with a reduction in circulating
estrogen (24–26).
Gram-positive lactobacilli are facultative anaerobic bacteria,
whose adherence to the vaginal mucosal epithelia appears to form
an important line of defense against pathogens (27). There is no
definitive “normal” vaginal microbiota, but in the vast majority of
pregnant healthy women, lactobacilli dominate (23, 28, 29). Sev-
eral important aspects of the vaginal microbiota have been uncov-
ered recently, particularly by sequencing PCR-amplified universal
16S ribosomal DNA (rDNA): (1) the healthy vaginal microbiota
is dominated by a few Lactobacillus species (30); (2) the detection
of Lactobacillus iners, Atopobium vaginae, and bacterial vaginosis-
associated bacteria 1, 2, and 3 (BVAB), is apparent in women with
BV (30–32). Due to some variations within sequencing techniques,
selection of suitable PCR primers, and sufficient depth, future
studies may yet reveal more important profiles of healthy versus
infected women (33, 34).
Although relatively few 16S DNA studies have been used with
samples from pregnant women, indications are that the micro-
biota does fluctuate during this time. Some researchers have
suggested that there are up to five different community state
types (CSTs) of bacteria, clusters generated based on similarity
in vaginal bacterial composition, in asymptomatic pregnant and
non-pregnant women (23, 35). Three of the CSTs (I, II, III) are
dominated by Lactobacillus, namely L. iners, L. crispatus, and L.
jensenii and/or L. gasseri. Two others, CST IV-A and CST IV-B
have low relative abundance of Lactobacillus spp. and are com-
posed of Peptoniphilus, Anaerococcus, Corynebacterium, Finegoldia,
and Prevotella (CST IV-A), and Atopobium, Sneathia, Gardnerella,
Ruminococcaceae, Parvimonas, and Mobiluncus (CST IV-B) (23).
Such studies have suggested that the vaginal microbiota composi-
tion of pregnant women has a higher abundance of L. vaginalis,
L. crispatus, L. gasseri, and L. jensenii, but lower CST IV-B bac-
teria, and is more stable than non-pregnant women (23, 28),
with L. crispatus, promoting stability (36). This remains to be
verified, but it may be due to hormonal changes. With advanc-
ing gestational age, the relative abundance of Lactobacillus spp.
increases while that of anaerobe or strict-anaerobe microbial
species decreases (37).
Bacterial vaginosis is essentially a polymicrobial dysbiosis, char-
acterized by an alteration in the endogenous vaginal microflora
with an absent or decreased proportion of lactobacilli and domi-
nance of G. vaginalis, Prevotella bivia, Mobiluncus sp., Mycoplasma
hominis, and A. vaginae (23, 35, 38, 39). Aerobic vaginitis (AE) is an
inflammatory condition in which organisms, such as Escherichia
coli and Staphylococcus aureus dominate (40). In many clinical
units, the diagnosis of BV involves using a Gram stain Nugent scor-
ing system with or without the Amsel criteria (a vaginal pH >4.5,
an amine fishy odor when vaginal fluid is mixed with potassium
chloride, the presence of clue cells) (41, 42). A Nugent score of 7–
10 seen microscopically as a near absence of rod shaped lactobacilli
and high abundance of pathogenic morphotypes is considered BV
(42). However, the reliability of the Nugent score has recently been
questioned (29). Indeed, sequencing of the vaginal microbiota
of women with BV reveals a diverse array of bacteria, including
the presence of L. iners (32, 43, 44). Improvement in diagnos-
tic accuracy for BV can be accomplished by using a DNA level
of ≥109 copies/mL for G. vaginalis and ≥108 copies/mL for A.
vaginae (45).
The prevalence of BV can vary between populations, but it
remains common during pregnancy, where it is associated with a
40% increase in the risk of PTB (46). Women with an abnormal
vaginal flora in their first trimester of pregnancy have a higher risk
of delivering preterm (39). Although an earlier Cochrane Review
(47) suggested that antibiotic treatment of abnormal vaginal flora
(intermediate flora or BV) before 20 weeks of gestation may reduce
the risk of PTB, a recent Cochrane Review concluded that antibi-
otic treatment of BV does not reduce the risk of PTB, regardless of
when (before 20 weeks or after 20 weeks of gestation) the treatment
is given (48). Some of these organisms possess sialidase activity,
which has been associated with an increased risk of PTB (49). Sial-
idases are hydrolytic enzymes that play a role in down-regulating
the innate response by degrading immunoglobin-A (IgA), and
it has been used in some diagnostic kits for this reason. Higher
LPS concentrations, mostly from P. bivia (50), and the concen-
trations of pro-inflammatory cytokines IL-1β, IL-6, and IL-8 have
been found to be elevated in the cervico-vaginal fluid of preg-
nant women with BV (51). The elevation in vaginal pH above
4.5 is a feature of BV, and this displaces L. crispatus, but not L.
iners, which has adapted to upregulate genes for carbohydrate
metabolism (52).
In African American and Hispanic women, a higher abun-
dance of Mycoplasma and lower abundance of BVAB3 is asso-
ciated with an increased risk of PTB in the second trimester (53).
This is unlikely due to race per se, but rather cultural and social
aspects. Other pathogens, such as Leptotrichia, Sneathia, BVAB1,
and Mobiluncus spp. appear in higher abundance prior to 16 weeks
gestation in women with a previous history of PTB and who
deliver preterm (54). Yet, such findings are not universal, and other
studies, albeit small, have reported no difference in the vaginal
microbial composition between women who have a spontaneous
PTB and those who deliver at term (37, 55).
Future microbiome studies should focus on the functionality
of organisms in the vagina, uterus, and perhaps even the placenta
(56). This should include the use of metabolomic analysis to help
understand how the vaginal microbiome may influence the risk
of PTB.
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ROLE OF IMMUNE-MEDIATORS IN PTL
The balance of pro and anti-inflammatory cytokines, produced by
CD4+ T helper (Th) cells, is important in predicting pregnancy
outcomes. In early pregnancy, a modest Th1 pro-inflammatory
environment promotes successful implantation and placentation
(57). As pregnancy progresses, there is a predominance of Th2
anti-inflammatory cytokines including IL-4 and IL-10, which
maintain uterine quiescence (57). Disruption of the Th1/Th2
balance favoring the predominance of Th1 pro-inflammatory
cytokines such as IL-1, IL-6, and TNFα may be responsible for
some cases of PTL (7). Chemokines, such as IL-8, chemokine lig-
and (CCL)-2, 3, 4, and 5 attract decidual leukocytes and lead to
the recruitment of additional pro-inflammatory cytokines that
amplify the inflammatory cascade (58, 59). In the choriodecidua,
levels of CCL2, 3, 4, and 5 are increased in women undergoing
PTL both with and without infection when compared to women
at term not in labor (59). In the amniotic fluid, levels of IL-1β,
IL-6, IL-8, TNFα, CCL3, 4, and 5 are elevated in women with
threatened PTL, especially in the presence of intra-amniotic infec-
tion, as are IL-1β, IL-6, IL-8, TNFα, and CCL2 in the cervical fluid
(60–65). IL-6 is increased in the umbilical blood of infants born
to mothers with chorioamnionitis (65–67). Furthermore, IL-1β,
IL-6, and IL-8 concentrations are increased in maternal plasma
women with preterm premature rupture of the membranes and
chorioamnionitis (64, 68).
Anti-inflammatory cytokines maintain pregnancy quiescence
by inhibiting the production of pro-inflammatory cytokines and
PGs (69, 70). IL-10 expression in the placenta is lower in women
who give birth preterm with chorioamnionitis compared to sam-
ples obtained from women who underwent elective terminations
in their second trimester of pregnancy (71). The same has been
observed in women in term labor with chorioamnionitis com-
pared to women at term not in labor (71). Amniotic fluid con-
centrations of IL-10 are not different between preterm and term
delivery, while cervico-vaginal levels of IL-4 and IL-10 are often
below the level of detection using current assays (72, 73). Data
regarding the role of maternal plasma IL-10 in mediating PTB
remain conflicting. Some studies report decreased plasma IL-10
concentrations with PTB compared to term (1), whereas others
have found an association between elevated plasma IL-10 with
an increased risk of pre-eclampsia or intrauterine growth restric-
tion, which may in turn lead to PTB (74). Overall, the positive
and negative predictive values of any single specific cytokine or
chemokine for PTB is limited (75) although the examination of
interactions with a multifactor dimensionality reduction analysis
between multiple cytokines within the maternal–fetal compart-
ments, rather than a single cytokine, may better predict the risk of
PTB (76).
PREBIOTICS AND PROBIOTICS FOR PREVENTION OF PTB
Prebiotics are indigestible food ingredients such as dietary fiber,
resistant starch, and oligosaccharides. They confer health ben-
efits by “causing significant changes in the composition of the
gut microflora with increased and reduced numbers of poten-
tially health-promoting bacteria and potentially harmful species,
respectively” (77, 78). The prebiotics galacto-oligosaccharide
(GOS), fructo-oligosaccharides (FOS), and lactulose have been
shown to provide substrates for the growth of lactobacilli and bifi-
dobacteria, suggesting that they may contribute to the beneficial
effects of probiotics. Prebiotics also possess immune-regulatory
functions (79–81) and in particular immune-saccharides are
known to induce activation of the innate immune system (81).
Prebiotic FOS increases the level of IL-27 concentrations in human
milk, which may help prevent the onset of allergic disorders in their
children (82). There is anecdotal evidence to suggest that prebiotic-
containing food may reduce the risk of PTB (83). Of interest, one
study reported that dried fruits and garlic that contained antimi-
crobial and prebiotic compounds were associated with a reduced
risk of spontaneous PTB (84).
Probiotics are defined as “live microorganisms, which when
administered in adequate amounts, confer a health benefit on the
host” (85). A number of meta-analyses of clinical trials with probi-
otics have confirmed that probiotics are both safe and effective for
the treatment and/or prevention of numerous infectious and/or
inflammatory diseases (86–89). Lactobacillus and Bifidobacterium
are the most commonly studied probiotics. Supplementation with
Bifidobacterium lactis in preterm infants reduces pathogenic Enter-
obacteriaceae and Clostridium spp. counts (90). Bifidobacteria are
present in large abundance in the intestinal flora, but they can
also be detected in the vagina. Probiotic lactobacilli play a poten-
tial beneficial role in human reproduction and maintenance of
healthy urinary and reproductive tracts (91).
The use of antibiotics to treat BV in non-pregnant and preg-
nant women remains the method of choice, unchanged in many
decades, and still too often ineffective. Metronidazole and clin-
damycin, by far the most used agents, do not restore vaginal lacto-
bacilli abundance, which may account for relapses in some women;
and prolonged use promotes the development of drug resistance
(27, 92). The need for new treatment for BV that restores micro-
biota homeostasis and acidity without undesirable side effects has
led investigators and patients to study probiotics. Human stud-
ies have provided evidence that probiotic lactobacilli can reduce
BV recurrence and increase lactobacilli abundance in the vagina
of pregnant and non-pregnant women (93–95). The use of lacto-
bacilli as an adjuvant therapy has also shown promise in lowering
BV recurrence rates (92). Indeed, the adjunctive use of L. rhamno-
sus GR-1 and L. reuteri RC-14 with metronidazole has been shown
to improve actual cure of BV (96, 97).
Probiotic intervention in pregnancy is generally acceptable with
good compliance among pregnant women (98). A recent meta-
analysis of randomized clinical trials demonstrated that the use
of probiotics Lactobacillus and Bifidobacterium during pregnancy
had no effect on the incidence of Cesarean section, birth weight,
or gestational age (99).
Oral administration of 109–1011 colony-forming units (cfu) of
lactobacilli is the standard dose believed to be required for passage
through the intestine and subsequent improvement of gut and
vaginal health (27, 93, 100, 101). There are many variables that
influence vaginal colonization by lactobacilli including glycogen
level, substances used in vaginal washing, the use of antibiotics, and
the ability of lactobacilli to produce substances such as hydrogen
peroxide (102–104). Bodean et al. (92) reported that oral admin-
istration of L. acidophilus and L. bifidus was more effective than
the vaginal route in reducing BV occurrence in antibiotic-treated
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non-pregnant women. However, the probiotic composition of the
oral capsule was different from the vaginal capsule (L. rhamnosus,
L. acidophilus, S. thermophilus, and L. bulgaricus) in that study,
and the mechanism seems unclear. Furthermore, the treatment
duration was longer for patients who received the oral capsule
than those who received vaginal capsules (92). An advantage of
the oral route is that it may reduce pathogen ascendance from the
rectum to perineum and vagina,while a concern of the intravaginal
approach for some women may be the more invasive instillation
of microbes.
A number of mechanisms whereby lactobacilli defend against
pathogens in the vaginal environment have been described, albeit
mostly from in vitro studies. These include the production of
antimicrobial substances, competitive exclusion with pathogenic
bacteria and fungi, acidification of the vaginal area, and modula-
tion of the immune system (40). Endogenous lactobacilli maintain
the vaginal pH <4.5 by metabolizing glycogen secreted by vagi-
nal mucosal epithelia and produce lactic acid, which is a potent
microbicide against potential reproductive tract infections (105,
106). The acidic environment of a healthy vagina creates a hostile
environment for BV-associated pathogens while favoring lacto-
bacilli growth (105, 107). It may also help to prevent viruses, such
as HIV, from infecting the host (108, 109).
The anti-inflammatory property of lactobacilli has been shown
to be important in the control of mucosal and systemic inflamma-
tion (110). L. rhamnosus GR-1 supernatant (GR-1 SN) enhances
IL-10 and colony-stimulating factor 3 (CSF3) production in
mouse macrophages (111). In primary human placental tro-
phoblast cells, GR-1 SN increases IL-10 and CSF3 production
via JAK/STAT and MAPK pathways, down-regulates LPS-induced
TNFα output through c-Jun-N-terminal kinases (JNKs) inhibi-
tion, and increases the expression of the PG metabolizing enzyme
PGDH in a sex-dependent fashion (112–114). When adminis-
tered intra-peritoneally to pregnant mice, GR-1 SN reduces LPS-
induced PTB in association with a decrease in pro-inflammatory
cytokines and an increase in anti-inflammatory cytokines in
maternal plasma and the amniotic fluid (115).
The effect of lactobacilli on the immune system and their
vaginal colonization ability can be species/strain specific. In
the mouse gut, L. plantarum and L. rhamnosus GG exacerbate
inflammation and the development of dextran sulfate sodium
(DSS)-induced colitis while L. paracasei is protective (116). In
the human vagina, L. rhamnosus GR-1 and L. reuteri RC-14
but not the intestinal probiotic L. rhamnosus GG persist up to
19 days (117). Intra-vaginal instillation of L. rhamnosus GR-1
has been shown to upregulate some antimicrobial activity in
premenopausal women (118). A combination of B. bifidum, B.
infantis, L. acidophilus, L. casei, L. salivarius, and Lactococcus
lactis has been reported to provide a wider antimicrobial spec-
trum, better stimulation of IL-10 production, and suppression of
pro-inflammatory cytokines in cultured human peripheral blood
mononuclear cells compared to the individual strains (119). A
combination of the bacteriocin-like inhibitory substances (BLIS)
from the L. rhamnosus L60 and L. fermentum L23 can reduce
the growth of group B streptococcal isolates obtained from preg-
nant women more effectively than each Lactobacillus strain alone
(120).
Lipoteichoic acid (LTA) on the cell surface of lactobacilli
can also stimulate macrophages to secrete immune-mediators.
Improved anti-inflammatory activity in a murine model of colitis
in vivo has been observed when LTA is removed or substituted
(121–123). L. rhamnosus GR-1 supernatant reduces LPS-induced
PTB and associated systemic and intrauterine inflammatory
cytokines in pregnant mice (115). The supernatant of lactobacilli
also has anti-inflammatory properties in cultured human placen-
tal trophoblast cells, decidual cells, monocytes, and macrophages
(112–114, 124, 125). In human decidual cells challenged with E.
coli, supernatant of L. rhamnosus CNCM I-4036 was found to be
more effective than the live bacteria counterpart in the suppression
of pro-inflammatory cytokine production (126). These studies
imply that administration of supernatant from lactobacilli may
promote desirable effects and represent an alternative for the pre-
vention and/or treatment of inflammatory disorders such as some
cases of PTB. The identification of these bioactive metabolite(s)
remains to be achieved.
Future clinical studies should consider not only the sample
size and design but also the appropriate probiotic strain(s), dose
and duration of treatment, and route of administration. Until a
sufficiently large study is performed in which the rate of PTB is
high enough to note a reduction due to an intervention (127), we
can only say that currently, the administration of a few probiotic
strains is safe for use in pregnancy and shows promise in confer-
ring health benefits, of which potentially reducing the risk of PTB
is one.
REFERENCES
1. Makhseed M, Raghupathy R, El-Shazly S, Azizieh F, Al-Harmi JA, Al-Azemi
MM. Pro-inflammatory maternal cytokine profile in preterm delivery. Am J
Reprod Immunol (2003) 49:308–18. doi:10.1034/j.1600-0897.2003.00038.x
2. Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of
preterm birth. Lancet (2008) 371:75–84. doi:10.1016/S0140-6736(08)60074-4
3. Goldenberg RL, Hauth JC, Andrews WW. Intrauterine infection and
preterm delivery. N Engl J Med (2000) 342:1500–7. doi:10.1056/
NEJM200005183422007
4. Timmons BC, Reese J, Socrate S, Ehinger N, Paria BC, Milne GL, et al.
Prostaglandins are essential for cervical ripening in LPS-mediated preterm
birth but not term or antiprogestin-driven preterm ripening. Endocrinology
(2014) 155:287–98. doi:10.1210/en.2013-1304
5. Shoji T, Yoshida S, Mitsunari M, Miyake N, Tsukihara S, Iwabe T, et al. Involve-
ment of p38 MAP kinase in lipopolysaccharide-induced production of pro-
and anti-inflammatory cytokines and prostaglandin E(2) in human choriode-
cidua. J Reprod Immunol (2007) 75:82–90. doi:10.1016/j.jri.2007.05.002
6. Romero R, Durum S, Dinarello CA, Oyarzun E, Hobbins JC, Mitchell
MD. Interleukin-1 stimulates prostaglandin biosynthesis by human amnion.
Prostaglandins (1989) 37:13–22. doi:10.1016/0090-6980(89)90028-2
7. Challis JR, Lockwood CJ, Myatt L, Norman JE, Strauss JF III, Petraglia
F. Inflammation and pregnancy. Reprod Sci (2009) 16:206–15. doi:10.1177/
1933719108329095
8. Olgun NS, Reznik SE. The matrix metalloproteases and endothelin-1 in
infection-associated preterm birth. Obstet Gynecol Int (2010) 2010:657039.
doi:10.1155/2010/657039
9. Maymon E, Romero R, Pacora P, Gomez R, Mazor M, Edwin S, et al. A role for
the 72 kDa gelatinase (MMP-2) and its inhibitor (TIMP-2) in human parturi-
tion, premature rupture of membranes and intraamniotic infection. J Perinat
Med (2001) 29:308–16. doi:10.1515/JPM.2001.044
10. Fujimoto T, Parry S, Urbanek M, Sammel M, Macones G, Kuivaniemi H, et al.
A single nucleotide polymorphism in the matrix metalloproteinase-1 (MMP-
1) promoter influences amnion cell MMP-1 expression and risk for preterm
premature rupture of the fetal membranes. J Biol Chem (2002) 277:6296–302.
doi:10.1074/jbc.M107865200
Frontiers in Immunology | Inflammation February 2015 | Volume 6 | Article 62 | 4
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Yang et al. Probiotics and preterm birth prevention
11. Park KH, Chaiworapongsa T, Kim YM, Espinoza J, Yoshimatsu J, Edwin S,
et al. Matrix metalloproteinase 3 in parturition, premature rupture of the
membranes, and microbial invasion of the amniotic cavity. J Perinat Med
(2003) 31:12–22. doi:10.1515/JPM.2003.002
12. Tency I. Inflammatory response in maternal serum during preterm labour.
Facts Views Vis Obgyn (2014) 6:19–30.
13. Yoon BH, Oh SY, Romero R, Shim SS, Han SY, Park JS, et al. An elevated amni-
otic fluid matrix metalloproteinase-8 level at the time of mid-trimester genetic
amniocentesis is a risk factor for spontaneous preterm delivery. Am J Obstet
Gynecol (2001) 185:1162–7. doi:10.1067/mob.2001.117678
14. Gotsch F, Romero R, Kusanovic JP, Mazaki-Tovi S, Pineles BL, Erez O, et al. The
fetal inflammatory response syndrome. Clin Obstet Gynecol (2007) 50:652–83.
doi:10.1097/GRF.0b013e31811ebef6
15. Buhimschi CS, Dulay AT, Abdel-Razeq S, Zhao G, Lee S, Hodgson EJ, et al. Fetal
inflammatory response in women with proteomic biomarkers characteristic of
intra-amniotic inflammation and preterm birth. BJOG (2009) 116:257–67.
doi:10.1111/j.1471-0528.2008.01925.x
16. Pacora P, Chaiworapongsa T, Maymon E, Kim YM, Gomez R, Yoon BH,
et al. Funisitis and chorionic vasculitis: the histological counterpart of the
fetal inflammatory response syndrome. J Matern Fetal Neonatal Med (2002)
11:18–25. doi:10.1080/jmf.11.1.18.25
17. Pavcnik-Arnol M, Lucovnik M, Kornhauser-Cerar L, Premru-Srsen T, Hojker
S, Derganc M, et al. Lipopolysaccharide-binding protein as marker of fetal
inflammatory response syndrome after preterm premature rupture of mem-
branes. Neonatology (2014) 105:121–7. doi:10.1159/000356735
18. Goldenberg RL, Andrews WW, Goepfert AR, Faye-Petersen O, Cliver SP, Carlo
WA, et al. The Alabama Preterm Birth Study: umbilical cord blood Ure-
aplasma urealyticum and Mycoplasma hominis cultures in very preterm new-
born infants. Am J Obstet Gynecol (2008) 198: 43.e1–5. doi:10.1016/j.ajog.2007.
07.033
19. Gravett MG, Hitti J, Hess DL, Eschenbach DA. Intrauterine infection and
preterm delivery: evidence for activation of the fetal hypothalamic-pituitary-
adrenal axis. Am J Obstet Gynecol (2000) 182:1404–13. doi:10.1067/mob.2000.
106180
20. Challis JR, Sloboda DM, Alfaidy N, Lye SJ, Gibb W, Patel FA, et al.
Prostaglandins and mechanisms of preterm birth. Reproduction (2002)
124(1):1–17. doi:10.1530/rep.0.1240001
21. Farage M, Maibach H. Lifetime changes in the vulva and vagina. Arch Gynecol
Obstet (2006) 273:195–202.1. doi:10.1007/s00404-005-0079-x
22. Spear GT, French AL, Gilbert D, Zariffard MR, Mirmonsef P, Sullivan TH, et al.
Human alpha-amylase present in lower-genital-tract mucosal fluid processes
glycogen to support vaginal colonization by Lactobacillus. J Infect Dis (2014)
210(7):1019–28. doi:10.1093/infdis/jiu231
23. Romero R, Hassan SS, Gajer P, Tarca AL, Fadrosh DW, Nikita L, et al. The
composition and stability of the vaginal microbiota of normal pregnant
women is different from that of non-pregnant women. Microbiome (2014)
2:4. doi:10.1186/2049-2618-2-4
24. Cauci S, Driussi S, De Santo D, Penacchioni P, Iannicelli T, Lanzafame P, et al.
Prevalence of bacterial vaginosis and vaginal flora changes in peri- and post-
menopausal women. J Clin Microbiol (2002) 40:2147–52. doi:10.1128/JCM.40.
6.2147-2152.2002
25. Gupta S, Kumar N, Singhal N, Kaur R, Manektala U. Vaginal microflora in
postmenopausal women on hormone replacement therapy. Indian J Pathol
Microbiol (2006) 49:457–61.
26. Hummelen R, Macklaim JM, Bisanz JE, Hammond JA, McMillan A, Vongsa
R, et al. Vaginal microbiome and epithelial gene array in post-menopausal
women with moderate to severe dryness. PLoS One (2011) 6:e26602. doi:10.
1371/journal.pone.0026602
27. Othman M, Neilson JP, Alfirevic Z. Probiotics for preventing preterm labour.
Cochrane Database Syst Rev (2007) 1:CD005941. doi:10.1002/14651858.
CD005941.pub2
28. Aagaard K, Riehle K, Ma J, Segata N, Mistretta TA, Coarfa C, et al. A metage-
nomic approach to characterization of the vaginal microbiome signature in
pregnancy. PLoS One (2012) 7:e36466. doi:10.1371/journal.pone.0036466
29. Chaban B, Links MG, Jayaprakash TP, Wagner EC, Bourque DK, Lohn Z,
et al. Characterization of the vaginal microbiota of healthy Canadian women
through the menstrual cycle. Microbiome (2014) 2:23. doi:10.1186/2049-2618-
2-23
30. Lamont RF, Sobel JD, Akins RA, Hassan SS, Chaiworapongsa T, Kusanovic
JP, et al. The vaginal microbiome: new information about genital tract flora
using molecular based techniques. BJOG (2011) 118:533–49. doi:10.1111/j.
1471-0528.2010.02840.x
31. Verstraelen H, Verhelst R, Claeys G, Temmerman M, Vaneechoutte M. Culture-
independent analysis of vaginal microflora: the unrecognized association of
Atopobium vaginae with bacterial vaginosis. Am J Obstet Gynecol (2004)
191:1130–2. doi:10.1016/j.ajog.2004.04.013
32. Fredricks DN, Fiedler TL, Marrazzo JM. Molecular identification of bacte-
ria associated with bacterial vaginosis. N Engl J Med (2005) 353:1899–911.
doi:10.1056/NEJMoa043802
33. Gloor GB, Hummelen R, Macklaim JM, Dickson RJ, Fernandes AD, MacPhee R,
et al. Microbiome profiling by illumina sequencing of combinatorial sequence-
tagged PCR products. PLoS One (2010) 5:e15406. doi:10.1371/journal.pone.
0015406
34. Walther-Antonio MR, Jeraldo P, Berg Miller ME, Yeoman CJ, Nelson KE, Wil-
son BA, et al. Pregnancy’s stronghold on the vaginal microbiome. PLoS One
(2014) 9:e98514. doi:10.1371/journal.pone.0098514
35. Ravel J, Gajer P, Abdo Z, Schneider GM, Koenig SS, McCulle SL, et al. Vagi-
nal microbiome of reproductive-age women. Proc Natl Acad Sci U S A (2011)
108(Suppl 1):4680–7. doi:10.1073/pnas.1002611107
36. Verstraelen H, Verhelst R, Claeys G, De Backer E, Temmerman M, Vanee-
chouttee M, et al. Longitudinal analysis of the vaginal microflora in preg-
nancy suggests that L. crispatus promotes the stability of the normal vagi-
nal microflora and that L. gasseri and/or L. iners are more conducive to the
occurrence of abnormal vaginal microflora. BMC Microbiol (2009) 9:116.
doi:10.1186/1471-2180-9-116
37. Romero R, Hassan SS, Gajer P, Tarca AL, Fadrosh DW, Bieda J, et al. The vaginal
microbiota of pregnant women who subsequently have spontaneous preterm
labor and delivery and those with a normal delivery at term. Microbiome (2014)
2:18. doi:10.1186/2049-2618-2-18
38. Schwebke JR, Muzny CA, Josey WE. Role of Gardnerella vaginalis in the
pathogenesis of bacterial vaginosis: a conceptual model. J Infect Dis (2014)
210:338–43. doi:10.1093/infdis/jiu089
39. van de Wijgert JH, Borgdorff H, Verhelst R, Crucitti T, Francis S, Verstraelen
H, et al. The vaginal microbiota: what have we learned after a decade of molec-
ular characterization? PLoS One (2014) 9:e105998. doi:10.1371/journal.pone.
0105998
40. Donders GG, Van Calsteren K, Bellen G, Reybrouck R, Van den Bosch T, Ripha-
gen I, et al. Predictive value for preterm birth of abnormal vaginal flora, bac-
terial vaginosis and aerobic vaginitis during the first trimester of pregnancy.
BJOG (2009) 116:1315–24. doi:10.1111/j.1471-0528.2009.02237.x
41. Reid G, Bocking A. The potential for probiotics to prevent bacterial vaginosis
and preterm labor. Am J Obstet Gynecol (2003) 189:1202–8. doi:10.1067/S0002-
9378(03)00495-2
42. Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis
is improved by a standardized method of gram stain interpretation. J Clin
Microbiol (1991) 29:297–301.
43. Hummelen R, Fernandes AD, Macklaim JM, Dickson RJ, Changalucha J, Gloor
GB, et al. Deep sequencing of the vaginal microbiota of women with HIV. PLoS
One (2010) 5:e12078. doi:10.1371/journal.pone.0012078
44. Jakobsson T, Forsum U. Lactobacillus iners: a marker of changes in the vaginal
flora? J Clin Microbiol (2007) 45:3145. doi:10.1128/JCM.00558-07
45. Menard JP, Fenollar F, Henry M, Bretelle F, Raoult D. Molecular quantifica-
tion of Gardnerella vaginalis and Atopobium vaginae loads to predict bacterial
vaginosis. Clin Infect Dis (2008) 47:33–43. doi:10.1086/588661
46. Ugwumadu AH. Bacterial vaginosis in pregnancy. Curr Opin Obstet Gynecol
(2002) 14:115–8. doi:10.1086/588661
47. McDonald HM, Brocklehurst P, Gordon A. Antibiotics for treating bacter-
ial vaginosis in pregnancy. Cochrane Database Syst Rev (2007) 1:CD000262.
doi:10.1002/14651858.CD000262.pub3
48. Brocklehurst P, Gordon A, Heatley E, Milan SJ. Antibiotics for treating bacte-
rial vaginosis in pregnancy. Cochrane Database Syst Rev (2013) 1:CD000262.
doi:10.1002/14651858.CD000262.pub4
49. Smayevsky J, Canigia LF, Lanza A, Bianchini H. Vaginal microflora asso-
ciated with bacterial vaginosis in nonpregnant women: reliability of sial-
idase detection. Infect Dis Obstet Gynecol (2001) 9:17–22. doi:10.1155/
S1064744901000047
www.frontiersin.org February 2015 | Volume 6 | Article 62 | 5
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Yang et al. Probiotics and preterm birth prevention
50. Aroutcheva A, Ling Z, Faro S. Prevotella bivia as a source of lipopolysaccharide
in the vagina. Anaerobe (2008) 14:256–60. doi:10.1016/j.anaerobe.2008.08.002
51. Mitchell C, Marrazzo J. Bacterial vaginosis and the cervicovaginal immune
response. Am J Reprod Immunol (2014) 71:555–63. doi:10.1111/aji.12264
52. Macklaim JM, Fernandes AD, Di Bella JM, Hammond JA, Reid G, Gloor GB.
Comparative meta RNA-seq of the vaginal microbiota and differential expres-
sion by Lactobacillus iners in health and dysbiosis. Microbiome (2013) 1:12.
doi:10.1186/2049-2618-1-12
53. Wen A, Srinivasan U, Goldberg D, Owen J, Marrs CF, Misra D, et al. Selected
vaginal bacteria and risk of preterm birth: an ecological perspective. J Infect Dis
(2014) 209:1087–94. doi:10.1093/infdis/jit632
54. Nelson DB, Hanlon A, Nachamkin I, Haggerty C, Mastrogiannis DS, Liu C, et al.
Early pregnancy changes in bacterial vaginosis-associated bacteria and preterm
delivery. Paediatr Perinat Epidemiol (2014) 28:88–96. doi:10.1111/ppe.12106
55. Hyman RW, Fukushima M, Jiang H, Fung E, Rand L, Johnson B, et al. Diversity
of the vaginal microbiome correlates with preterm birth. Reprod Sci (2014)
21:32–40. doi:10.1177/1933719113488838
56. Aagaard K, Ma J, Antony KM, Ganu R, Petrosino J, Versalovic J, et al. The
placenta harbors a unique microbiome. Sci Transl Med (2014) 6:237ra265.
doi:10.1126/scitranslmed.3008599
57. Wilczynski JR. Th1/Th2 cytokines balance – yin and yang of reproduc-
tive immunology. Eur J Obstet Gynecol Reprod Biol (2005) 122:136–43.
doi:10.1016/j.ejogrb.2005.03.008
58. Esplin MS, Peltier MR, Hamblin S, Smith S, Fausett MB, Dildy GA, et al.
Monocyte chemotactic protein-1 expression is increased in human gesta-
tional tissues during term and preterm labor. Placenta (2005) 26:661–71.
doi:10.1016/j.placenta.2004.09.012
59. Hamilton SA, Tower CL, Jones RL. Identification of chemokines associated
with the recruitment of decidual leukocytes in human labour: potential novel
targets for preterm labour. PLoS One (2013) 8:e56946. doi:10.1371/journal.
pone.0056946
60. El-Bastawissi AY, Williams MA, Riley DE, Hitti J, Krieger JN. Amniotic
fluid interleukin-6 and preterm delivery: a review. Obstet Gynecol (2000)
95:1056–64. doi:10.1016/S0029-7844(00)00875-9
61. Hitti J, Hillier SL, Agnew KJ, Krohn MA, Reisner DP, Eschenbach DA, et al.
Vaginal indicators of amniotic fluid infection in preterm labor. Obstet Gynecol
(2001) 97:211–9. doi:10.1016/S0029-7844(00)01146-7
62. Jun JK, Yoon BH, Romero R, Kim M, Moon JB, Ki SH, et al. Interleukin 6 deter-
minations in cervical fluid have diagnostic and prognostic value in preterm
premature rupture of membranes. Am J Obstet Gynecol (2000) 183:868–73.
doi:10.1067/mob.2000.109034
63. Coultrip LL, Lien JM, Gomez R, Kapernick P, Khoury A, Grossman JH. The
value of amniotic fluid interleukin-6 determination in patients with preterm
labor and intact membranes in the detection of microbial invasion of the
amniotic cavity. Am J Obstet Gynecol (1994) 171:901–11. doi:10.1016/S0002-
9378(94)70057-5
64. von Minckwitz G, Grischke EM, Schwab S, Hettinger S, Loibl S, Aulmann M,
et al. Predictive value of serum interleukin-6 and -8 levels in preterm labor
or rupture of the membranes. Acta Obstet Gynecol Scand (2000) 79:667–72.
doi:10.1034/j.1600-0412.2000.079008667.x
65. Holst RM, Hagberg H, Wennerholm UB, Skogstrand K, Thorsen P, Jacobs-
son B. Prediction of microbial invasion of the amniotic cavity in women with
preterm labour: analysis of multiple proteins in amniotic and cervical fluids.
BJOG (2011) 118:240–9. doi:10.1111/j.1471-0528.2010.02765.x
66. Chaiworapongsa T, Romero R, Kim JC, Kim YM, Blackwell SC, Yoon BH, et al.
Evidence for fetal involvement in the pathologic process of clinical chorioam-
nionitis. Am J Obstet Gynecol (2002) 186:1178–82. doi:10.1067/mob.2002.
124042
67. Holst RM, Mattsby-Baltzer I, Wennerholm UB, Hagberg H, Jacobsson B.
Interleukin-6 and interleukin-8 in cervical fluid in a population of Swedish
women in preterm labor: relationship to microbial invasion of the amniotic
fluid, intra-amniotic inflammation, and preterm delivery. Acta Obstet Gynecol
Scand (2005) 84:551–7. doi:10.1111/j.0001-6349.2005.00708.x
68. Torbe A, Czajka R, Kordek A, Rzepka R, Kwiatkowski S, Rudnicki J. Maternal
serum proinflammatory cytokines in preterm labor with intact membranes:
neonatal outcome and histological associations. Eur Cytokine Netw (2007)
18:102–7. doi:10.1684/ecn.2007.0092
69. Bowen JM, Chamley L, Mitchell MD, Keelan JA. Cytokines of the placenta and
extra placental membranes: biosynthesis, secretion and roles in establishment
of pregnancy in women. Placenta (2002) 23:239–56. doi:10.1053/plac.2001.
0781
70. Keelan JA, Blumenstein M, Helliwell RJ, Sato TA, Marvin KW, Mitchell MD.
Cytokines, prostaglandins and parturition – a review. Placenta (2003) 24(Suppl
A):S33–46. doi:10.1053/plac.2002.0948
71. Hanna N, Bonifacio L, Weinberger B, Reddy P, Murphy S, Romero R, et al.
Evidence for interleukin 10-mediated inhibition of cyclo-oxygenase-2 expres-
sion and prostaglandin production in preterm human placenta. Am J Reprod
Immunol (2006) 55:19–27. doi:10.1111/j.1600-0897.2005.00342.x
72. Puchner K, Iavazzo C, Gourgiotis D, Boutsikou M, Baka S, Hassiakos D, et al.
Mid-trimester amniotic fluid interleukins (IL-1beta, IL-10 and IL-18) as pos-
sible predictors of preterm delivery. In vivo (2011) 25:141–8.
73. Vogel I, Goepfert AR, Thorsen P, Skogstrand K, Hougaard DM, Curry AH,
et al. Early second-trimester inflammatory markers and short cervical length
and the risk of recurrent preterm birth. J Reprod Immunol (2007) 75:133–40.
doi:10.1016/j.jri.2007.02.008
74. Ferguson KK, McElrath TF, Chen YH, Mukherjee B, Meeker JD. Longitudinal
profiling of inflammatory cytokines and C-reactive protein during uncom-
plicated and preterm pregnancy. Am J Reprod Immunol (2014) 72:326–36.
doi:10.1111/aji.12265
75. Menon R, Torloni MR, Voltolini C, Torricelli M, Merialdi M, Betran AP,
et al. Biomarkers of spontaneous preterm birth: an overview of the liter-
ature in the last four decades. Reprod Sci (2011) 18:1046–70. doi:10.1177/
1933719111415548
76. Bhat G, Williams SM, Saade GR, Menon R. Biomarker interactions are bet-
ter predictors of spontaneous preterm birth. Reprod Sci (2014) 21:340–50.
doi:10.1177/1933719113497285
77. Gibson GR, Probert HM, Loo JV, Rastall RA, Roberfroid MB. Dietary modu-
lation of the human colonic microbiota: updating the concept of prebiotics.
Nutr Res Rev (2004) 17:259–75. doi:10.1079/NRR200479
78. Roberfroid M. Prebiotics: the concept revisited. J Nutr (2007) 137:830s–7s.
79. Watson D, O’Connell Motherway M, Schoterman MH, van Neerven RJ,
Nauta A, van Watson D, et al. Selective carbohydrate utilization by lactobacilli
and bifidobacteria. J Appl Microbiol (2013) 114:1132–46. doi:10.1111/jam.
12105
80. Ben XM, Li J, Feng ZT, Shi SY, Lu YD, Chen R, et al. Low level of galacto-
oligosaccharide in infant formula stimulates growth of intestinal bifidobacteria
and Lactobacilli. World J Gastroenterol (2008) 14:6564–8. doi:10.3748/wjg.14.
6564
81. Song SK, Beck BR, Kim D, Park J, Kim J, Kim HD, et al. Prebiotics as immunos-
timulants in aquaculture: a review. Fish Shellfish Immunol (2014) 40:40–8.
doi:10.1016/j.fsi.2014.06.016
82. Kubota T, Shimojo N, Nonaka K, Yamashita M, Ohara O, Igoshi Y, et al. Prebi-
otic consumption in pregnant and lactating women increases IL-27 expression
in human milk. Br J Nutr (2014) 111:625–32. doi:10.1017/S0007114513003036
83. Otsuki K, Tokunaka M, Oba T, Nakamura M, Shirato N, Okai T. Administration
of oral and vaginal prebiotic lactoferrin for a woman with a refractory vaginitis
recurring preterm delivery: appearance of lactobacillus in vaginal flora followed
by term delivery. J Obstet Gynaecol Res (2014) 40:583–5. doi:10.1111/jog.12171
84. Myhre R, Brantsaeter AL, Myking S, Eggesbo M, Meltzer HM, Haugen M, et al.
Intakes of garlic and dried fruits are associated with lower risk of spontaneous
preterm delivery. J Nutr (2013) 143:1100–8. doi:10.3945/jn.112.173229
85. FAO/WHO. Joint FAO/WHO Expert Consultation on Evaluation of Health and
Nutritional Properties of Probiotics in Food. London, ON (2001). Available from:
ftp://ftp.fao.org/docrep/fao/009/a0512e/a0512e00.pdf
86. Chen AC,Chung MY,Chang JH,Lin HC. Pathogenesis implication for necrotiz-
ing enterocolitis prevention in preterm very-low-birth-weight infants. J Pediatr
Gastroenterol Nutr (2014) 58:7–11. doi:10.1097/MPG.0b013e3182a7dc74
87. Goldenberg JZ, Ma SS, Saxton JD, Martzen MR, Vandvik PO, Thorlund K,
et al. Probiotics for the prevention of Clostridium difficile-associated diar-
rhea in adults and children. Cochrane Database Syst Rev (2013) 5:CD006095.
doi:10.1002/14651858.CD006095.pub3
88. Yang Y, Guo Y, Kan Q, Zhou XG, Zhou XY, Li Y, et al. A meta-analysis of probi-
otics for preventing necrotizing enterocolitis in preterm neonates. Braz J Med
Biol Res (2014) 47:804–10. doi:10.1590/1414-431X20143857
Frontiers in Immunology | Inflammation February 2015 | Volume 6 | Article 62 | 6
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Yang et al. Probiotics and preterm birth prevention
89. Grin PM, Kowalewska PM, Alhazzan W, Fox-Robichaud AE. Lactobacillus for
preventing recurrent urinary tract infections in women: meta-analysis. Can J
Urol (2013) 20:6607–14.
90. Szajewska H, Guandalini S, Morelli L, Van Goudoever JB, Walker A. Effect of
Bifidobacterium animalis subsp lactis supplementation in preterm infants: a
systematic review of randomized controlled trials. J Pediatr Gastroenterol Nutr
(2010) 51:203–9. doi:10.1097/MPG.0b013e3181dc0d93
91. Reid G, Brigidi P, Burton JP, Contractor N, Duncan S, Fargier E, et al. Microbes
central to human reproduction. Am J Reprod Immunol (2014) 73(1):1–11.
doi:10.1111/aji.12319
92. Bodean O, Munteanu O, Cirstoiu C, Secara D, Cirstoiu M. Probiotics-a helpful
additional therapy for bacterial vaginosis. J Med Life (2013) 6:434–6.
93. Homayouni A, Bastani P, Ziyadi S, Mohammad-Alizadeh-Charandabi S, Ghal-
ibaf M, Mortazavian AM, et al. Effects of probiotics on the recurrence of bac-
terial vaginosis: a review. J Low Genit Tract Dis (2014) 18:79–86. doi:10.1097/
LGT.0b013e31829156ec
94. Nishijima K, Shukunami K, Kotsuji F. Probiotics affects vaginal flora in preg-
nant women, suggesting the possibility of preventing preterm labor. J Clin
Gastroenterol (2005) 39:447–8. doi:10.1097/01.mcg.0000159269.58480.4b
95. Reid G, Charbonneau D, Erb J, Kochanowski B, Beuerman D, Poehner R, et al.
Oral use of Lactobacillus rhamnosus GR-1 and L. fermentum RC-14 signifi-
cantly alters vaginal flora: randomized, placebo-controlled trial in 64 healthy
women. FEMS Immunol Med Microbiol (2003) 35:131–4. doi:10.1016/S0928-
8244(02)00465-0
96. Martinez RC, Franceschini SA, Patta MC, Quintana SM, Gomes BC, De Mar-
tinis EC, et al. Improved cure of bacterial vaginosis with single dose of tinida-
zole (2 g), Lactobacillus rhamnosus GR-1, and Lactobacillus reuteri RC-14: a
randomized, double-blind, placebo-controlled trial. Can J Microbiol (2009)
55:133–8. doi:10.1139/w08-102
97. Anukam K, Osazuwa E, Ahonkhai I, Ngwu M, Osemene G, Bruce AW, et al.
Augmentation of antimicrobial metronidazole therapy of bacterial vaginosis
with oral probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-
14: randomized, double-blind, placebo controlled trial. Microbes Infect (2006)
8:1450–4. doi:10.1016/j.micinf.2006.01.003
98. Lindsay KL, Brennan L, McAuliffe FM. Acceptability of and compliance with
a probiotic capsule intervention in pregnancy. Int J Gynaecol Obstet (2014)
125:279–80. doi:10.1016/j.ijgo.2014.01.004
99. Dugoua JJ, Machado M, Zhu X, Chen X, Koren G, Einarson TR, et al. Probiotic
safety in pregnancy: a systematic review and meta-analysis of randomized con-
trolled trials of Lactobacillus, Bifidobacterium, and Saccharomyces spp. J Obstet
Gynaecol Can (2009) 31:542–52.
100. Reid G, Beuerman D, Heinemann C, Bruce AW. Probiotic Lactobacillus dose
required to restore and maintain a normal vaginal flora. FEMS Immunol Med
Microbiol (2001) 32:37–41. doi:10.1111/j.1574-695X.2001.tb00531.x
101. Morelli L, Zonenenschain D, Del Piano M, Cognein P. Utilization of the intesti-
nal tract as a delivery system for urogenital probiotics. J Clin Gastroenterol
(2004) 38(6 Suppl):S107–10. doi:10.1097/01.mcg.0000128938.32835.98
102. Vallor AC, Antonio MA, Hawes SE, Hillier SL. Factors associated with
acquisition of, or persistent colonization by, vaginal lactobacilli: role of
hydrogen peroxide production. J Infect Dis (2001) 184(11):1431–6. doi:10.
1086/324445
103. Baeten JM, Hassan WM, Chohan V, Richardson BA, Mandaliya K, Ndinya-
Achola JO, et al. Prospective study of correlates of vaginal Lactobacillus coloni-
sation among high-risk HIV-1 seronegative women. Sex Transm Infect (2009)
85(5):348–53. doi:10.1136/sti.2008.035451
104. Mirmonsef P, Hotton AL, Gilbert D, Burgad D, Landay A, Weber KM, et al. Free
glycogen in vaginal fluids is associated with Lactobacillus colonization and low
vaginal pH. PLoS One (2014) 9(7):e102467. doi:10.1371/journal.pone.0102467
105. Donati L, Di Vico A, Nucci M, Quagliozzi L, Spagnuolo T, Labianca A, et al.
Vaginal microbial flora and outcome of pregnancy. Arch Gynecol Obstet (2010)
281:589–600. doi:10.1007/s00404-009-1318-3
106. O’Hanlon DE, Moench TR, Cone RA. Vaginal pH and microbicidal lactic
acid when lactobacilli dominate the microbiota. PLoS One (2013) 8:e80074.
doi:10.1007/s00404-009-1318-3
107. Borges S, Silva J, Teixeira P. The role of lactobacilli and probiotics in main-
taining vaginal health. Arch Gynecol Obstet (2014) 289:479–89. doi:10.1007/
s00404-013-3064-9
108. Cadieux P, Burton J, Gardiner G, Braunstein I, Bruce AW, Kang CY, et al. Lac-
tobacillus strains and vaginal ecology. JAMA (2002) 287:1940–1. doi:10.1001/
jama.287.15.1935
109. Petrova MI, van den Broek M, Balzarini J, Vanderleyden J, Lebeer S. Vaginal
microbiota and its role in HIV transmission and infection. FEMS Microbiol
Rev (2013) 37:762–92. doi:10.1111/1574-6976.12029
110. Kemgang TS, Kapila S, Shanmugam VP, Kapila R. Cross-talk between probi-
otic lactobacilli and host immune system. J Appl Microbiol (2014) 117:303–19.
doi:10.1111/jam.12521
111. Kim SO, Sheikh HI, Ha SD, Martins A, Reid G. G-CSF-mediated inhibition
of JNK is a key mechanism for Lactobacillus rhamnosus-induced suppres-
sion of TNF production in macrophages. Cell Microbiol (2006) 8:1958–71.
doi:10.1111/j.1462-5822.2006.00763.x
112. Yeganegi M, Leung CG, Martins A, Kim SO, Reid G, Challis JR, et al. Lacto-
bacillus rhamnosus GR-1 stimulates colony-stimulating factor 3 (granulocyte)
(CSF3) output in placental trophoblast cells in a fetal sex-dependent manner.
Biol Reprod (2011) 84:18–25. doi:10.1095/biolreprod.110.085167
113. Yeganegi M, Leung CG, Martins A, Kim SO, Reid G, Challis JR, et al. Lactobacil-
lus rhamnosus GR-1 induced IL-10 production in human placental trophoblast
cells involves activation of JAK/STAT and MAPK pathways. Reprod Sci (2010)
17:1043–51. doi:10.1177/1933719110377237
114. Yeganegi M, Watson CS, Martins A, Kim SO, Reid G, Challis JR, et al. Effect of
Lactobacillus rhamnosus GR-1 supernatant and fetal sex on lipopolysaccharide-
induced cytokine and prostaglandin-regulating enzymes in human placen-
tal trophoblast cells: implications for treatment of bacterial vaginosis and
prevention of preterm labor. Am J Obstet Gynecol (2009) 200(532):e531–8.
doi:10.1016/j.ajog.2008.12.032
115. Yang S, Li W, Challis JR, Reid G, Kim SO, Bocking AD. Probiotic Lactobacil-
lus rhamnosus GR-1 supernatant prevents lipopolysaccharide-induced preterm
birth and reduces inflammation in pregnant CD-1 mice. Am J Obstet Gynecol
(2014) 211: 44.e1–44.e12. doi:10.1016/j.ajog.2014.01.029
116. Mileti E, Matteoli G, Iliev ID, Rescigno M. Comparison of the immunomod-
ulatory properties of three probiotic strains of lactobacilli using complex
culture systems: prediction for in vivo efficacy. PLoS One (2009) 4:e7056.
doi:10.1371/journal.pone.0007056
117. Gardiner GE, Heinemann C, Bruce AW, Beuerman D, Reid G. Persistence of
Lactobacillus fermentum RC-14 and Lactobacillus rhamnosus GR-1 but not L.
rhamnosus GG in the human vagina as demonstrated by randomly ampli-
fied polymorphic DNA. Clin Diagn Lab Immunol (2002) 9:92–6. doi:10.1128/
CDLI.9.1.92-96.2002
118. Kirjavainen PK, Laine RM, Carter D, Hammond J-A, Reid G. Expression of anti
microbial defense factors in vaginal mucosa following exposure of Lactobacillus
rhamnosus GR-1. Int J Probiotics (2008) 3:99–106.
119. Timmerman HM, Niers LE, Ridwan BU, Koning CJ, Mulder L, Akkemans LM,
et al. Design of a multispecies probiotic mixture to prevent infectious compli-
cations in critically ill patients. Clin Nutr (2007) 26:450–9. doi:10.1016/j.clnu.
2007.04.008
120. Ruiz FO, Gerbaldo G, Garcia MJ, Giordano W, Pascual L, Barberis IL, et al.
Synergistic effect between two bacteriocin-like inhibitory substances produced
by lactobacilli strains with inhibitory activity for Streptococcus agalactiae. Curr
Microbiol (2012) 64:349–56. doi:10.1007/s00284-011-0077-0
121. Grangette C, Nutten S, Palumbo E, Morath S, Hermann C, Dewulf J, et al.
Enhanced antiinflammatory capacity of a Lactobacillus plantarum mutant syn-
thesizing modified teichoic acids. Proc Natl Acad Sci U S A (2005) 102:10321–6.
doi:10.1073/pnas.0504084102
122. Claes IJ, Lebeer S, Shen C, Verhoeven TL, Dilissen E, De Hertogh G, et al.
Impact of lipoteichoic acid modification on the performance of the probiotic
Lactobacillus rhamnosus GG in experimental colitis. Clin Exp Immunol (2010)
162:306–14. doi:10.1111/j.1365-2249.2010.04228.x
123. Mohamadzadeh M, Pfeiler EA, Brown JB, Zadeh M, Gramarossa M, Man-
aglia E, et al. Regulation of induced colonic inflammation by Lactobacillus
acidophilus deficient in lipoteichoic acid. Proc Natl Acad Sci U S A (2011)
108(Suppl 1):4623–30. doi:10.1073/pnas.1005066107
124. Li W, Yang S, Kim SO, Reid G, Challis JR, Bocking AD. Lipopolysaccharide-
induced profiles of cytokine, chemokine, and growth factors produced by
human decidual cells are altered by Lactobacillus rhamnosus GR-1 supernatant.
Reprod Sci (2014) 21:939–47. doi:10.1177/1933719113519171
www.frontiersin.org February 2015 | Volume 6 | Article 62 | 7
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Yang et al. Probiotics and preterm birth prevention
125. Lin YP, Thibodeaux CH, Pena JA, Ferry GD, Versalovic J. Probiotic Lactobacil-
lus reuteri suppress proinflammatory cytokines via c-Jun. Inflamm Bowel Dis
(2008) 14:1068–83. doi:10.1002/ibd.20448
126. Bermudez-Brito M, Munoz-Quezada S, Gomez-Llorente C, Romero F, Gil
A. Lactobacillus rhamnosus and its cell-free culture supernatant differentially
modulate inflammatory biomarkers in Escherichia coli-challenged human den-
dritic cells. Br J Nutr (2014) 111:1727–37. doi:10.1017/S0007114513004303
127. Krauss-Silva L, Moreira ME,Alves MB, Braga A, Camacho KG, Batista MR, et al.
A randomised controlled trial of probiotics for the prevention of spontaneous
preterm delivery associated with bacterial vaginosis: preliminary results. Trials
(2011) 12:239. doi:10.1186/1745-6215-12-239
Conflict of Interest Statement: The Guest Associate Editor, Jeffrey Keelan, declares
that despite being affiliated to the same institution as author, John R. G. Challis,
there has been no conflict of interest during the review and handling of this man-
uscript. The authors declare that the research was conducted in the absence of any
commercial or financial relationships that could be construed as a potential conflict
of interest.
Received: 05 November 2014; paper pending published: 08 December 2014; accepted:
01 February 2015; published online: 17 February 2015.
Citation: Yang S, Reid G, Challis JRG, Kim SO, Gloor GB and Bocking AD (2015)
Is there a role for probiotics in the prevention of preterm birth? Front. Immunol. 6:62.
doi: 10.3389/fimmu.2015.00062
This article was submitted to Inflammation, a section of the journal Frontiers in
Immunology.
Copyright © 2015 Yang , Reid, Challis, Kim, Gloor and Bocking . This is an open-access
article distributed under the terms of the Creative Commons Attribution License (CC
BY). The use, distribution or reproduction in other forums is permitted, provided the
original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Immunology | Inflammation February 2015 | Volume 6 | Article 62 | 8
